Neuropediatrics 1997; 28(1): 33-36
DOI: 10.1055/s-2007-973663
Original articles

© Hippokrates Verlag GmbH Stuttgart

Expression Studies of CLN3 Protein

W. Kaczmarski, E. Kida1 , A. Lach1 , R. Rubenstein2 , N. Zhong3 , K. E. Wisniewski1
  • 1Departments of Pathological Neurobiology, NYS Institute for Basic Research in Developmental Disabilities, S.I., NY, USA
  • 2Departments of Molecular Neurovirology, NYS Institute for Basic Research in Developmental Disabilities, S.I., NY, USA
  • 3Departments of Human Genetics, NYS Institute for Basic Research in Developmental Disabilities, S.I., NY, USA
Further Information

Publication History

Publication Date:
13 March 2007 (online)

Abstract

Expression of the gene for Batten disease (CLN3) was studied in Escherichia coil and in a cell-free rabbit reticulocyte expression systems. A full-length recombinant fusion CLN3 protein was not produced in the bacterial systems used. However, both N-terminal fragment encompassing 246 amino acids and short C-terminal fragment containing 428-438 amino acids of the CLN3 protein were successfully overexpressed in bacteria. Further studies showed that the C-terminal sequence of the CLN3 protein corresponding to the 356-438 amino acid residues was responsible for inhibition of protein synthesis in bacteria. The full-length CLN3 gene product was readily synthesized in vitro in the cell-free rabbit reticulocyte expression system. The product obtained, corresponding to core CLN3 protein, showed an approximate molecular weight of 43 kDa. Immunoprecipitation of this product with pAb to 4-19 amino acids of the CLN3 protein allows us to suggest that CLN3 protein translation starts at Met-1.

    >